Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of three blockbuster antibiotics — levofloxacin, moxifloxacin and piperacillin/tazobactam — will be the primary factors contributing to a decline of more than 15 percent in the community-acquired pneumonia drug market though 2018.
Popularity: unranked [?]
